Tandem Diabetes Care Inc
Company Profile
Business description
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
Contact
12400 High Bluff Drive
San DiegoCA92130
USAT: +1 858 366-6900
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
2,500
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,444.40 | 33.10 | 0.35% |
| CAC 40 | 8,699.71 | 30.42 | 0.35% |
| DAX 40 | 26,140.13 | 13.83 | 0.05% |
| Dow JONES (US) | 53,885.10 | 464.02 | -0.85% |
| FTSE 100 | 10,867.89 | 20.41 | -0.19% |
| HKSE | 25,599.66 | 69.38 | 0.27% |
| NASDAQ | 26,348.35 | 15.09 | -0.06% |
| Nikkei 225 | 65,563.79 | 119.47 | -0.18% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,709.96 | 13.59 | -0.18% |
| S&P/ASX 200 | 9,262.70 | 33.90 | 0.37% |
| SSE Composite Index | 3,929.44 | 29.09 | 0.75% |